ArticleTranslational cancer research2026
A mitochondrial function-based prognostic model for hepatocellular carcinoma uncovers MRPS15 as a key driver of tumor progression through oxidative phosphorylation.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is highly heterogeneous with unpredictable outcomes. Mitochondrial dysfunction drives HCC progression, but its prognostic implications remain unclear. This study aimed to develop a mitochondrial-related prognostic model for HCC. Methods: We analyzed transcriptomic data from 370 HCC patients from The Cancer Genome Atlas (TCGA) using consensus clustering of mitochondrial pathway genes. A mitochondrial-associated scoring model (MASM) was developed via least absolute shrinkage and selection operator (LASSO) and Cox regression, validated across independent cohorts [GSE116174 and the International Cancer Genome Consortium Liver Cancer-RIKEN, Japan (ICGC-LIRI)]. Functional roles of MRPS15, a key gene in the model, were investigated through Results: Consensus clustering identified three mitochondrial subtypes with distinct metabolic profiles: subtype A exhibited elevated oxidative phosphorylation (OXPHOS) and preserved metabolic homeostasis; subtype B showed adaptive metabolic reprogramming; subtype C displayed selective activation of biosynthetic pathways despite widespread mitochondrial dysfunction. The MASM prognostic signature, comprising eight mitochondrial genes, achieved predictive accuracy with area under the curve (AUC) values of 0.805, 0.751, and 0.742 for 1-, 3-, and 5-year survival, respectively, and showed favorable trends compared with clinical staging. MRPS15 was validated as a critical regulator of HCC cell proliferation, invasion, migration, and apoptosis, primarily through sustaining OXPHOS and redox homeostasis. Conclusions: This study establishes a mitochondrial-based classification and eight-gene MASM model for HCC, which stratifies patients into three subtypes with distinct metabolic, genomic, and immune profiles. The model outperforms traditional staging in survival prediction. MRPS15 is validated as a key oncogenic driver sustaining OXPHOS. These findings provide a framework for personalized therapy and warrant prospective clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.